Alembic Pharmaceuticals Adjusts Evaluation Amidst Market Fluctuations and Profit Decline

Alembic Pharmaceuticals has recently undergone an evaluation adjustment, reflecting a revision in its score. This change is attributed to various underlying trends and metrics that characterize the company's current market position.
The stock is currently priced at 943.15, having seen fluctuations with a 52-week high of 1,296.15 and a low of 725.60. Over the past year, Alembic Pharmaceuticals has reported a return of -17.69%, which contrasts with the broader market's performance, as indicated by the BSE500's return of -4.41%.

In terms of financial health, the company maintains a low Debt to EBITDA ratio of 0.67 times, suggesting a strong capacity to service its debt. Additionally, the Return on Capital Employed (ROCE) stands at 11.5, indicating an attractive valuation relative to its capital employed. However, the company has experienced a decline in operating profit, with an annual growth rate of -9.13% over the last five years.

Despite these challenges, Alembic Pharmaceuticals benefits from high institutional holdings at 20.42%, which may provide a level of stability and informed analysis of its fundamentals.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.